We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns Indian Generics Maker For Multiple GMP Violations
FDA Warns Indian Generics Maker For Multiple GMP Violations
July 19, 2011
The FDA has warned Indian active pharmaceutical ingredient (API) and generics maker Zydus Group, a division of Cadila Healthcare, for a number of current good manufacturing practice (cGMP) violations, including incomplete test data.